Morgan Stanley Trevena Inc Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.16 - $100.0 $23,166 - $14.5 Million	-144,792 Reduced 42.68%	194,466 $30,000
Q2 2022 Oct 27, 2022	BUY	$0.2 - $0.5 $8,634 - $21,586	43,172 Added 14.58%	339,258 $140,000
Q2 2022 Aug 15, 2022	BUY	$0.2 - $0.5 $8,634 - $21,586	43,172 Added 14.58%	339,258 $140,000
Q1 2022 Oct 27, 2022	SELL	$0.41 - $0.63 $17,700 - $27,198	-43,172 Reduced 12.73%	296,086 $163,000
Q1 2022 May 13, 2022	SELL	$0.41 - $0.63 $132,953 - $204,293	-324,276 Reduced 52.27%	296,086 $163,000
Q4 2021 Feb 14, 2022	BUY	$0.57 - $1.29 $101,393 - $229,469	177,883 Added 40.2%	620,362 $361,000
Q3 2021 Nov 15, 2021	BUY	$1.11 - $1.7 $491,151 - $752,214	442,479 New	442,479 $544,000

Ticker TRVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 173,680,992
Market Cap $292M
Description
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.